Where can researchers source third-party tested CJC-1295?

Midwest Peptide supplies research-grade CJC-1295 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.

Age Verification

You must be 21 years or older to access this website. All products are for research use only.

Are you 21 years of age or older?

By entering, you confirm that you are at least 21 years old and agree to our terms of service.

Memorial Day: 15% off code MEMDAY15Memorial Day Sale — 15% off site-wide with code MEMDAY15

Free shipping on every orderFree shipping on every order

5% off with Zelle or Apple CashSave an extra 5% when you pay with Zelle or Apple Cash

Bulk pricing discounts up to 18%Bulk pricing discounts up to 18% off

GH Secretagogue Comparison: GHRH vs GHRP Research | Midwest Peptide

Cagrilintide in Research: A Review of Long-Acting Amylin Analog StudiesPrev|GHRH and GHRP Synergy Research: Why Combinations Are Studied TogetherNext

Growth Hormone Secretagogue Comparison: A Comparative Literature Review

Q: Is CJC-1295 approved for human use?

No. CJC-1295 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.

CJC-1295 / Ipamorelin · Published April 8, 2026 · Updated May 18, 2026 · 8 min read

Quick Answer

Growth hormone secretagogue comparison research reviews GHRH analogs and GHRPs side by side, including selectivity profiles, pharmacokinetics, and downstream biomarker effects across preclinical models. This review supports researchers selecting between sermorelin, tesamorelin, CJC-1295, ipamorelin, and related research tools. For research use only, not for human consumption.

Growth Hormone Secretagogue Comparison: A Comparative Literature Review

Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.

The Two Major Secretagogue Families
GHRH Analogs Compared
GHRPs Compared
Combinations of GHRH and GHRP Secretagogues
Practical Considerations for Research Selection
Open Research Questions
Conclusion
Related Research Articles
Explore Related Products
Frequently Asked Questions
Glossary

Growth hormone secretagogue comparison research provides essential context for investigators selecting peptides for preclinical studies of the somatotropic axis. The secretagogue landscape includes a substantial number of peptides with overlapping but distinct profiles, and the comparative literature on these compounds is one of the more practically useful areas of GH research. As the comparative review component of the CJC-1295/Ipamorelin research cluster, this article reviews the published literature on how the major growth hormone secretagogues compare with each other in research models, with a focus on GHRH analogs, GHRPs, and the broader class of growth hormone releasing compounds.

Frequently Asked Questions

What is CJC-1295 in research contexts?

CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH). It is studied in research models as a long-acting GHRH receptor agonist that drives pulsatile growth hormone release from the pituitary.

What classes of growth hormone secretagogues are compared in research?

The two main classes are GHRH analogs (CJC-1295, Tesamorelin, Sermorelin) and GHRPs/ghrelin receptor agonists (Ipamorelin, GHRP-2, GHRP-6, MK-677). Research literature compares selectivity, half-life, pulse architecture, and side effect profiles across both classes.

What selectivity differences matter most in GH secretagogue research?

Ipamorelin is the most selective GHRP for GH release without raising cortisol or prolactin, while older GHRPs like GHRP-6 stimulate ghrelin-related appetite signaling and modest cortisol release. CJC-1295 acts only on the GHRH receptor with no off-target endocrine effects.

Is CJC-1295 approved for human use?

Glossary

Key terms used in this article.

GHRH: Growth hormone-releasing hormone, the hypothalamic peptide that stimulates pituitary growth hormone release.
DAC (Drug Affinity Complex): A maleimidopropionic acid linker on CJC-1295 that covalently binds serum albumin to extend half-life.
Pulsatile Release: The episodic, rhythmic secretion pattern characteristic of growth hormone from the anterior pituitary.
Pituitary Somatotroph: The anterior pituitary cell type that synthesizes and secretes growth hormone.
IGF-1: Insulin-like growth factor 1, the primary downstream mediator of growth hormone action, produced largely in the liver.
GHS-R1a: Growth hormone secretagogue receptor 1a, the ghrelin receptor through which ipamorelin signals.
GHRP: Growth hormone-releasing peptide, a class of synthetic ghrelin receptor agonists that stimulate GH release.
Ghrelin: The endogenous 28-amino-acid acylated peptide hormone that activates GHS-R1a and stimulates appetite and GH release.

More from the Blog

Continue exploring research insights and updates.

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Subcutaneous vs intranasal administration for CNS-targeted research peptides: how to choose between routes for DSIP, Selank, and Kisspeptin based on molecular size, brain access, pharmacokinetics, and the published literature.

May 5, 2026

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

FDA restricted compounded tirzepatide for human use when the shortage ended. The Research Use Only research peptide channel for tirzepatide (GLP-2 TZ) operates under entirely separate regulations.

May 5, 2026

For Research Use Only. The peptides discussed in this article are intended exclusively for in vitro and preclinical research. They are not approved for human use, are not drugs, and should never be administered to humans or to animals outside of a formal research protocol.

The Two Major Secretagogue Families

Growth hormone secretagogues fall into two broad mechanistic categories that differ in their receptor target and downstream signaling. The first category is the GHRH analogs, which act on the GHRH receptor on pituitary somatotroph cells. The second category is the growth hormone releasing peptides (GHRPs), which act on the growth hormone secretagogue receptor (GHS-R1a, also known as the ghrelin receptor) on the same cells. Combinations of peptides from both categories are studied in research models for their proposed synergistic effects on growth hormone release.

The GHRH analog family includes natural GHRH, sermorelin (GHRH(1-29)), tesamorelin (a stabilized GHRH analog approved for clinical use in HIV-associated lipodystrophy research), CJC-1295 (with and without DAC), and several other research peptides developed through structure activity relationship studies on the GHRH(1-29) sequence. Each of these has its own pharmacokinetic profile and research applications.

The GHRP family includes GHRP-6 (the original member of the class), GHRP-2, hexarelin, and ipamorelin, along with several other selective and non selective ghrelin receptor agonists developed since the 1980s. Each member of this family has its own selectivity profile, with newer peptides generally being more selective for GH release without off target effects on cortisol, prolactin, or appetite-related signaling.

GHRH Analogs Compared

The major GHRH analogs differ primarily in their pharmacokinetic profiles and in the structural modifications used to stabilize them against proteolytic degradation in research models.

Natural GHRH has a very short half life in research animals due to rapid cleavage by dipeptidyl peptidase IV (DPP-IV) and other proteases. While natural GHRH has been studied extensively as the endogenous regulator of growth hormone release, its short half life makes it difficult to use as a research tool for studies requiring sustained signaling.

Sermorelin is the GHRH(1-29) fragment, which retains essentially full receptor binding activity while being chemically simpler than the full 44 amino acid GHRH peptide. Sermorelin is more stable than natural GHRH in some research conditions but still has a relatively short functional half life.

Tesamorelin is a stabilized GHRH analog with a hexenoyl modification at the N-terminus that protects against proteolytic cleavage. It has been studied extensively in clinical research for its effects on visceral adipose tissue in HIV-associated lipodystrophy, and it has a longer functional half life than natural GHRH or sermorelin in research models.

CJC-1295 (no DAC) is a tetrasubstituted GHRH analog with four amino acid modifications that protect against DPP-IV cleavage. Its functional half life is intermediate between sermorelin and the with DAC form, and it produces enhanced GH release with pulse kinetics that approximate stabilized endogenous GHRH activity in research models.

CJC-1295 (with DAC) adds a maleimido propionic acid linker that allows covalent binding to circulating serum albumin. This modification dramatically extends the functional half life to days rather than minutes or hours, producing sustained tonic GH stimulation rather than pulsatile release.

The choice between these GHRH analogs depends on the specific research question. Studies of pulsatile release patterns benefit from shorter acting peptides like sermorelin or CJC-1295 (no DAC), while studies of sustained tonic stimulation benefit from longer acting peptides like CJC-1295 (with DAC). For more on the no DAC form specifically, see our companion article on CJC-1295 No DAC research and GHRH analog pulse kinetics.

GHRPs Compared

The major GHRPs differ primarily in their selectivity for the GHS-R1a receptor and in their off target effects on cortisol, prolactin, and appetite-related signaling.

GHRP-6 was the first member of the class identified by Cyril Bowers and colleagues in the 1980s. It produces robust GH release in research models but is relatively non selective, with measurable effects on appetite signaling through hypothalamic ghrelin receptors and modest effects on cortisol and prolactin in some research conditions. GHRP-6 played a foundational role in the discovery of the ghrelin receptor system, but its broader profile limits its use for research applications requiring isolated GH effects.

GHRP-2 is structurally related to GHRP-6 and was developed in the same research program. It is generally described as having greater GH releasing potency than GHRP-6 in research models, but it shares similar broader effects on appetite and other endocrine pathways. Studies have used GHRP-2 in both basic research and in clinical contexts as a stronger but less selective GHRP option.

Hexarelin is another hexapeptide in the GHRP class that has been studied for its effects on the pituitary and on cardiac tissue, where the ghrelin receptor is also expressed. Hexarelin research has examined cardioprotective endpoints in rodent models in addition to GH release, expanding the scope of GHRP research beyond pituitary effects.

Ipamorelin is the most selective member of the major GHRP class. It produces GH release through the GHS-R1a receptor without significant effects on cortisol, prolactin, or appetite-related signaling in research models. Its selectivity has made it the preferred GHRP for research applications requiring isolated GH effects without confounding hormone changes. For more on Ipamorelin specifically, see our companion article on Ipamorelin research and selective GHRP ghrelin receptor binding studies.

Combinations of GHRH and GHRP Secretagogues

Beyond the comparison of individual peptides within each class, the comparative literature includes substantial research on combinations of GHRH analogs with GHRPs. The proposed synergy between these two pathways means that combinations have been one of the most active research configurations in the field. The pairing of CJC-1295 (no DAC) with Ipamorelin in the CJC-1295/Ipamorelin Blend is one example of such a combination, and it has been studied for its effects on combined GH release in research models.

Other combinations that have been studied include sermorelin plus various GHRPs, tesamorelin plus GHRPs in some research contexts, and natural GHRH plus GHRPs in foundational research on the synergy phenomenon. Each combination has its own specific profile, with the choice between them depending on the experimental question and the desired pharmacokinetic and selectivity characteristics.

For more on the conceptual basis for these combinations, see our companion article on GHRH GHRP synergy research and growth hormone models.

Practical Considerations for Research Selection

Several practical considerations guide the selection of secretagogues for specific research applications. The first is the desired pharmacokinetic profile: is the research question about pulsatile release patterns, sustained tonic stimulation, or some combination of both. The second is the desired selectivity profile: are off target effects on cortisol, prolactin, or appetite signaling acceptable for the experimental design, or do they need to be minimized. The third is the availability of comparative literature: which peptides have the most established research base in the specific area of interest.

For most research applications that require isolated, pulsatile GH release with clean endocrine profiles, the combination of CJC-1295 (no DAC) with Ipamorelin is one of the more useful research formulations available. For research that requires sustained tonic stimulation, the with DAC form of CJC-1295 may be more appropriate. For research on broader endocrine pathways, the less selective GHRPs may provide useful additional information at the cost of confounding effects.

Open Research Questions

Several open research questions remain in the comparative secretagogue literature. These include how the pulse kinetics of different GHRH analogs compare quantitatively in standardized rodent research models, how the selectivity profiles of newer GHRPs compare with the established profile of Ipamorelin, and how combined formulations of stabilized GHRH analogs with selective GHRPs compare with single peptide approaches in different research contexts. Each of these is a legitimate research opportunity for investigators selecting tools for the somatotropic axis.

Conclusion

Growth hormone secretagogue comparison research provides essential practical context for investigators studying the somatotropic axis in preclinical models. The major GHRH analogs and GHRPs each have distinct profiles that make them appropriate for different research questions, and the combinations of peptides from both classes provide additional research tools for studying combined pathway effects. For investigators using the CJC-1295/Ipamorelin Blend as a research tool, the comparative literature provides the broader landscape against which the specific properties of this combination can be evaluated.

For more on the full CJC-1295/Ipamorelin research cluster, see the pillar overview article and the supporting articles on each major topic.

The peptides discussed in this article are supplied by Midwest Peptide for research use only and are not intended for human administration.

Explore more peer-reviewed research and laboratory guides from our science team:

All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.

Tesamorelin 10mg, 99%+ purity, COA included
GHK-Cu 50mg, 99%+ purity, COA included
BPC-157 10mg, 99%+ purity, COA included

Browse All Research Peptides →

Age Verification

Growth Hormone Secretagogue Comparison: A Comparative Literature Review

Frequently Asked Questions

What is CJC-1295 in research contexts?

What classes of growth hormone secretagogues are compared in research?

What selectivity differences matter most in GH secretagogue research?

Is CJC-1295 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

The Two Major Secretagogue Families

GHRH Analogs Compared

GHRPs Compared

Combinations of GHRH and GHRP Secretagogues

Practical Considerations for Research Selection

Open Research Questions

Conclusion

Ready to Start Your Research?

Where can researchers source third-party tested CJC-1295?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?

Age Verification

Growth Hormone Secretagogue Comparison: A Comparative Literature Review

Frequently Asked Questions

What is CJC-1295 in research contexts?

What classes of growth hormone secretagogues are compared in research?

What selectivity differences matter most in GH secretagogue research?

Is CJC-1295 approved for human use?

Glossary

More from the Blog

Subcutaneous vs Intranasal: Choosing an Administration Route for DSIP, Selank, and Kisspeptin in Research

Can I Still Buy Compounded Tirzepatide? (2026 Research Context)

The Two Major Secretagogue Families

GHRH Analogs Compared

GHRPs Compared

Combinations of GHRH and GHRP Secretagogues

Practical Considerations for Research Selection

Open Research Questions

Conclusion

Related Research Articles

Explore Related Products

Ready to Start Your Research?

Where can researchers source third-party tested CJC-1295?

What's the Cheapest Way to Get Tirzepatide (GLP-2 TZ) for Research?